Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

multiple sclerosis/cefalàlgia

L'enllaç es desa al porta-retalls
14 resultats

Compositions and methods for the treatment of chronic pain

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1857/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051482 filed on 24 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into

Compositions and methods for the treatment of severe pain

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1838/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050917 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

Compositions and methods for the treatment of moderate to severe pain

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

Bi-pyridinyl derivatives as NK-1 antagonists

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
PRIORITY TO RELATED APPLICATIONS This application claims the benefit of European Application No. 05101324.1, filed Feb. 22, 2005, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Substance P is a naturally occurring undecapeptide belonging to the tachykinin

Compositions and methods for the treatment of neurologic diseases

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1834/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050909 filed on 3 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Cyclic triazo and diazo sodium channel blockers

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to triazine compounds and cyclic diazo analogs thereof having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. U.S. Pat. No. 4,649,139 discloses compounds of the formula

Cyclic triazo and diazo sodium channel blockers

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Application No. PCT/GB2009/050033, filed on Jan. 16, 2009, which claims the priority date of United Kingdom Application No. 0800741.1, filed on Jan. 16, 2008 the contents of both being hereby incorporated

Substituted triazoles as sodium channel blockers

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION The present invention is directed to a series of substituted triazole compounds. In particular, this invention is directed to substituted triazoles that are sodium channel blockers useful for the treatment and prevention of chronic and neuropathic pain. The compounds of the

Aromatic and heteroaromatic substituted amides

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF INVENTION The invention relates to a compound of formula ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance

Cannabinoid receptor modulators

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.

Cannabinoid receptor modulators

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions
Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge